Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis"

Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00616-18. doi: 10.1128/AAC.00616-18. Print 2018 Aug.

Claudio U Köser^{1

2}, Jan Heyckendorf^{3

4

5}, Sönke Andres⁶, Ioana D Olaru^{3

4}, Thomas Schön^{7

8}, Erik Sturegård⁹, Patrick Beckert^{2

4}, Viola Schleusener², Thomas A Kohl^{2

4}, Doris Hillemann⁶, Danesh Moradigaravand¹⁰, Julian Parkhill¹⁰, Sharon J Peacock^{1

10

11}, Stefan Niemann^{2

4}, Christoph Lange^{12

4

5

13}, Matthias Merker^{2

4}

¹ Department of Genetics, University of Cambridge, Cambridge, United Kingdom.
² Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
³ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
⁴ German Center for Infection Research (DZIF), Borstel, Germany.
⁵ International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
⁶ Division of Mycobacteriology (National Tuberculosis Reference Laboratory), Research Center Borstel, Borstel, Germany.
⁷ Department of Infectious Diseases and Clinical Microbiology, Kalmar County Hospital, Kalmar, Sweden.
⁸ Department of Clinical and Experimental Medicine, Division of Medical Microbiology, Linköping University, Linköping, Sweden.
⁹ Clinical Microbiology, Department of Translational Medicine, Lund University, Malmö, Sweden.
¹⁰ Wellcome Trust Sanger Institute, Hinxton, United Kingdom.
¹¹ London School of Hygiene & Tropical Medicine, London, United Kingdom.
¹² Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany [email protected].
¹³ Department of Medicine, Karolinska Institute, Stockholm, Sweden.

No abstract available

Publication types